title: Clinical differences between invasive pulmonary infection by Scedosporium apiospermum and invasive pulmonary aspergillosis.
abstract: Invasive pulmonary infection by Scedosporium apiospermum (IPSA) and invasive pulmonary aspergillosis (IPA) are clinically similar. Our objective was to identify clinical parameters that may differentiate IPSA from IPA. Ours was a prospective cohort study that included patients with different degrees of immunosuppression and respiratory isolation of S. apiospermum (SCA). Episodes of invasive infection were classified according to the EORTC and MSG criteria. Clinical variables corresponding to patients with IPSA were compared with those collected from patients with a diagnosis of IPA during the same period. Twenty-seven patients with positive culture for SCA from respiratory samples were evaluated. Of the 27 positive cultures, nine were classified as IPSA. When compared with the 89 patients with IPA, patients with IPSA were most likely to have received prophylaxis with either aerosolised (14.6% vs. 66.7%; P < 0.001) or intravenous amphotericin B (AMB; 4.5% vs. 44.4%; P = 0.002), to have prior episode of acute rejection (19% vs. 66.7%; P = 0.005), to have a later onset of infection after transplantation (251 days vs. 404 days; P = 0.009), and to have higher CD4(+) lymphocyte count (207.6 vs. 289.4; P = 0.005). Late-onset disease after transplantation and prophylaxis with AMB are more frequent in patients with IPSA compared with IPA.
authors.affiliation: Clinical Unit of Infectious Diseases, Reina Sofía University Hospital, Córdoba, Spain. juanjoco2005@yahoo.es
authors.forename: J J
authors.initials: JJ
authors.lastname: Castón
authors.forename: M J
authors.initials: MJ
authors.lastname: Linares
authors.forename: A
authors.initials: A
authors.lastname: Rivero
authors.forename: M
authors.initials: M
authors.lastname: Casal
authors.forename: J
authors.initials: J
authors.lastname: Torre-Cisneros
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D001230:Aspergillus / Q000302:isolation & purification / Q000472:pathogenicity*; D018890:Chemoprevention / Q000379:methods; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008172:Lung Diseases, Fungal / Q000382:microbiology* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000175:diagnosis / Q000382:microbiology* / Q000473:pathology*; D016377:Organ Transplantation / Q000009:adverse effects; D011446:Prospective Studies; D012307:Risk Factors; D021681:Scedosporium / Q000302:isolation & purification / Q000472:pathogenicity*; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B